Johnson & Johnson Covid-19 Vaccine: Approved in India
The Johnson & Johnson vaccine, known as JNJ-78436735 or Ad26.COV2.S has been developed by Janssen Pharmaceutica, a Belgium-based division of the company, in collaboration with Beth Israel Deaconess Medical Center, Boston.
It has an efficacy rate of 85.4% against severe disease and 93.1% against hospitalization.
Johnson and Johnson's single-dose vaccine has recently got approval by the Emergency Use Authorisation (EUA) to be launched in India, tweeted by Mansukh Mandaviya, Union Health Minister on Saturday.
The Central Drug Standard Control Organisation (CDSCO) approval comes as an important milestone for India.
With an eye on a potential third wave of the pandemic, the central government has now granted EUA to a total of five Covid-19 vaccines.
Unlike its US counterparts, Moderna and Pfizer vaccines, the Johnson & Johnson vaccine does not use messenger RNA (mRNA) to help the body build its defenses against the virus.
In this case, the gene of the coronavirus ’ signature spike protein is added to an adenovirus, a common virus that causes colds or flu-like symptoms.
When it is introduced into the body, delivers the instructions that teach human cells to make the spike protein.
That causes the immune system to react by making sufficient antibodies to attack the spike protein and provide specific immunity against this deadly virus.
Biological E, an important part of the global chain network will be supplying this one-dose vaccine to governments, different health authorities, organizations such as Gavi, and the COVAX facility.
According to the Strategic Advisory Group of Experts of WHO, the single dose (0.5 ml) Janssen Ad26.CoV2.S vaccine should be administered intramuscularly.
Vaccinate yourself, follow safety protocols to keep your friends and family COVID-FREE